Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Subscribe To Our Newsletter & Stay Updated
